Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE: Temozolomide and Nivolumab in MGMT Deficient Oesophagogastric Adenocarcinoma
NCT04984733Phase 2Completed
- Sponsor
- University of Southampton
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide, nivolumab in Oesophago-Gastric Adenocarcinoma, sponsored by University of Southampton. Started Sep 2021; status: completed.
02
Drugs
temozolomidenivolumab
03
Conditions
Oesophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT04984733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984733.